# Critical VNC Flaw in Eppendorf BioFlo 320 Bioreactors Exposes Biotech Labs to Remote Takeover


## The Threat


The Eppendorf BioFlo 320 bioreactor—a widely deployed piece of laboratory automation equipment used in pharmaceutical development, biotech research, and clinical manufacturing—contains a critical vulnerability that could allow attackers to remotely seize complete control of the device. The flaw, tracked as CVE-2026-7251, stems from a hard-coded password embedded in the device's Virtual Network Computing (VNC) remote access server, one of the industry's most antiquated remote desktop protocols.


The vulnerability is straightforward but devastating in a healthcare and biotech context. If a bioreactor has VNC enabled and is accessible over a network—either directly from the internet or through compromised internal networks—an attacker who knows the hard-coded password can connect remotely and take full command of the device's control interface. They would then have access to all operational parameters, process data, and potentially the ability to alter or sabotage ongoing bioprocessing runs. For facilities manufacturing therapeutic proteins, monoclonal antibodies, or vaccines, this translates to the ability to compromise product quality, contaminate batches, or cause equipment damage.


Compounding the severity, VNC traffic is transmitted without encryption by default. This means that any network segment where an attacker has visibility—whether through wireless eavesdropping, DNS hijacking, or a compromised internal network—could expose the hard-coded credentials in plaintext. Given that many lab networks operate with minimal network segmentation, this vulnerability creates a direct bridge from an attacker's reconnaissance tools to critical bioprocessing infrastructure.


## Severity and Impact


| Attribute | Details |

|---|---|

| CVE ID | CVE-2026-7251 |

| CVSS Score | 9.8 (CRITICAL) |

| CVSS Vector | CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:H |

| Attack Vector | Network |

| Attack Complexity | Low |

| Privileges Required | None |

| User Interaction | None |

| Scope | Unchanged |

| Confidentiality Impact | High |

| Integrity Impact | High |

| Availability Impact | High |

| CWE | CWE-259: Use of Hard-coded Password |


The 9.8 CVSS score reflects a vulnerability requiring no authentication, no user interaction, and no special network position—if the device is reachable, it can be exploited. An attacker with access to the network where the BioFlo 320 resides or with internet-facing exposure could compromise confidentiality (read all process data), integrity (alter parameters and output), and availability (halt or corrupt operations).


## Affected Products


  • Eppendorf BioFlo 320 Bioreactor — all firmware versions

    • The vulnerability affects every BioFlo 320 unit regardless of firmware version or deployment date. No hardware variants are excluded from the flaw.


    ## Mitigations


    Immediate Actions:


    1. Verify VNC Status — Check each BioFlo 320 to confirm whether VNC is currently enabled. While Eppendorf states VNC ships disabled by default and can only be enabled locally, organizations should independently verify this setting.


    2. Install Software Update — Eppendorf has released a permanent remediation in the form of a software update that entirely removes VNC functionality from the controller. Organizations should prioritize deploying Version 5.0 or later as soon as operational schedules allow.


    3. Enforce Role-Based Access Controls — Until the update is deployed, enable the device's security settings to restrict VNC configuration changes to Admin and Supervisor roles only. This prevents lower-privileged operators from inadvertently re-enabling VNC.


    Long-Term Recommendations:


  • Network Segmentation — BioFlo 320 devices should never be directly connected to the internet or business networks. Isolate them behind firewalls on dedicated laboratory networks with restricted ingress/egress rules.

  • Disable Remote Access — Unless remote monitoring is operationally necessary, keep VNC and all remote access disabled. Remote access multiplies attack surface exponentially.

  • Encrypted Remote Access — If remote access is required for legitimate operations (e.g., vendor support or remote troubleshooting), use VPN or other encrypted methods rather than unencrypted protocols like VNC.

  • Credential Rotation and Access Logging — After patching, audit all access logs for any unauthorized connections. Many biotech facilities lack audit trails for legacy equipment access.

  • Vendor Communication — Eppendorf has removed VNC configuration information from current documentation. This is a step toward responsible disclosure, but organizations should update their internal runbooks and training materials to exclude VNC remote access procedures.

    • ## References


  • Eppendorf Software Downloads: https://www.eppendorf.com/software-downloads
  • CISA Vulnerability Notification: CISA Alert (official notification source)
  • CWE-259: Use of Hard-coded Password: https://cwe.mitre.org/data/definitions/259.html

    • ---


    ## HackWire Analysis


    This vulnerability illuminates a critical gap in biotech infrastructure security: the assumption that laboratory equipment is "air-gapped" or inherently protected. In reality, BioFlo 320 bioreactors are deployed in facilities with increasingly connected networks—pharmaceutical companies need visibility into manufacturing operations, contract research organizations require remote vendor support, and clinical operations demand integration with enterprise systems. That connectivity, combined with a 15-year-old remote access protocol and hard-coded credentials, creates the exact conditions attackers systematically exploit in industrial and healthcare settings.


    The timing is worth noting. Pharmaceutical and biotech firms have faced coordinated ransomware campaigns targeting manufacturing environments. In 2024 alone, multiple organizations in the life sciences sector experienced attacks that disrupted vaccine or therapeutic production. A bioreactor compromised via this VNC flaw wouldn't trigger traditional intrusion detection—it looks like a technician logging in. An attacker could subtly alter fermentation parameters, contaminate batches, or steal proprietary bioprocess data months before anyone realizes something is wrong.


    What makes this particularly dangerous is that Eppendorf's "default disabled" posture gives organizations false confidence. Many facility managers don't verify actual configurations; they trust the vendor default. And once VNC is enabled (whether by a third-party integrator adding remote troubleshooting capability or by an insider), there's no easy way to know without direct inspection. The lack of built-in audit logging on the BioFlo 320 means an attacker could exfiltrate process recipes, production data, or cell culture parameters without detection.


    The real lesson: legacy industrial and laboratory equipment was never designed with network threats in mind. Patching CVE-2026-7251 is essential, but it's a band-aid on a larger problem—vendors must phase out hard-coded credentials entirely, implement encryption by default, and bake in audit trails. Until that happens, assume every piece of manufacturing equipment on a network is a potential entry point. — *HackWire Editorial*


    ## Related Coverage


  • Read more in our [Vulnerabilities](https://www.hackwire.news/category/vulnerabilities) coverage
  • Cross-reference with [Breaches](https://www.hackwire.news/category/breaches) and [Malware](https://www.hackwire.news/category/malware)
  • Stay current via the [HackWire homepage](https://www.hackwire.news/)